MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
MacroGenics expanded its royalty purchase agreement with Sagard Healthcare Partners for ZYNYZ, securing a $60 million upfront payment. The company may receive an additional $20 million in 2026 sales-based milestones, while royalty rights revert to MacroGenics once Sagard achieves a 1.7x or 2.0x return on investment.
Key figures
- Drug Name
- ZYNYZ (retifanlimab-dlwr)
- Deal Value Usd
- 60000000
- Reversion terms
- 1.7x investment by Sept 30, 2032 or 2.0x thereafter
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.